Safety of SF6(SonoVue®) Contrast Agent on Pharmacological Stress Echocardiogram.
Rogerio Gomes FurtadoDaniela do Carmo RassiLuciano Henrique MelatoAna Caroline Reinaldo de OliveiraPaula Meneses NunesPriscila Elias BaccelliSara Camila de Oliveira SantosVictor Emanuel SantosLuiz Rassi JuniorColandy Godoy NunesPublished in: Arquivos brasileiros de cardiologia (2021)
SonoVue® demonstrated safety during PSE. No cases of death, AMI, or anaphylactic reaction were observed. There was a lower incidence of minor side effects and arrhythmias in the group that received ECA, as well as a low incidence of mild allergic reactions.